THE ASSOCIATION OF P2Y12 INHIBITOR COPAYMENT REDUCTION WITH OUTCOMES AT HOSPITALS WITH AND WITHOUT MEDICATION ASSISTANCE PROGRAMS
Jacob A. Doll(University of Washington), Tracy Wang(Medical College of Wisconsin), Lisa A. Kaltenbach(Duke University), Christopher P. Cannon(Brigham and Women's Hospital), James M. Eudicone(University of Washington), David Cohen(University of Washington), Eric Peterson, Gregg C. Fonarow(UCLA Medical Center), Eileen Fonseca(University of Washington), Timothy D. Henry(Christ Hospital), Narinder Bhalla(University of Washington), Kevin Anstrom(PragmatIC (United Kingdom))
Cited by 0
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction
|Circulation|2010|4.8k
Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
|American Heart Journal|2005|2.1k
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
|Circulation|2006|2.1k
The Global Health and Economic Burden of Hospitalizations for Heart Failure
|Journal of the American College of Cardiology|2014|2k